We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Cryo-Save | LSE:CRYO | London | Ordinary Share | NL0009272137 | ORD EUR0.10 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 420.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMCRYO RNS Number : 7504M Cryo-Save Group NV 28 May 2010 28 May 2010 Cryo-Save Group N.V. Contract signed with Spanish insurance company Mutua Madrilena; update on France Cryo-Save Group N.V. (AIM/Euronext: CRYO, 'Cryo-Save' or 'the Group'), Europe's leading stem cell bank, announces the signing of the contract with Aresa Seguros de Salud, the health insurance company of the Spanish Mutua Madrileña Insurance Group. Mutua Madrileña, through Aresa, will offer its clients very beneficial conditions (reimbursement of EUR550 and in terms of storage time) for using Cryo-Save cryopreservation services related to stem cells from umbilical cord blood. Thanks to this partnership with Mutua Madrileña, one of the leading insurance companies in Spain with more than 1.8 million clients, many more Spanish parents will have easy access to the benefits of cryopreservation of stem cells of their newborns. Mr. Joaquim Lopez, Director of Aresa, states that: "This agreement is a further step in our strategy and commitment to provide our clients with the latest medical developments and services through the Leading Stem Cell Bank in Europe". Cryo-Save France SAS is preparing its response to Agence Française de Sécurité Sanitaire des Produits de Santé (Afssaps) after it has been informed that the authorisation for processing and storage of stem cells from the umbilical cord blood in France has been refused. Cryo-Save's quality control processes and state-of-the-art storage facilities, licensed and compliant with the respective EU directives, guarantee its clients a strict safety profile and the highest quality. Afssaps did not mention any quality related issues, but referred to legal restrictions in the French law related to stem cell storage and donation. Arnoud van Tulder, Chief Executive Officer of the Cryo-Save Group said: "The parents in France who opt for the storage of stem cells of their newborns remain our priority. We are confident that Afssaps will ultimately align its stem cell guidelines with those of the other EU countries. We expect the business impact will be temporary, however we will update the market if this expectation changes." Enquiries: +-------------------------------------+---------------------+ | Cryo-Save Group | + 31 (0)575 548998 | +-------------------------------------+---------------------+ | Arnoud van Tulder, Chief Executive | | | Officer | | +-------------------------------------+---------------------+ | Marc Waeterschoot, Executive | | | Director | | +-------------------------------------+---------------------+ | Daniel Stewart & Company plc | + 44 (0)20 7776 | | | 6550 | +-------------------------------------+---------------------+ | Simon Leathers/Emma Earl | | +-------------------------------------+---------------------+ | | | +-------------------------------------+---------------------+ +-------------------------------------+---------------------+ | College Hill (UK) | + 44 (0)20 7457 | | | 2020 | +-------------------------------------+---------------------+ | Adrian Duffield/Rozi Morris | | +-------------------------------------+---------------------+ | | | +-------------------------------------+---------------------+ | SPJ Financiële Communicatie | +31 (0)20 647 8181 | | Amstelveen (NL) | | +-------------------------------------+---------------------+ | Kees Jongsma/Léon Melens | | +-------------------------------------+---------------------+ About Cryo-Save With more than 130,000 samples saved, Cryo-Save is the leading stem cell bank in Europe and one of the fastest growing in the world. Driven by its international business strategy, Cryo-Save is now represented in 38 countries on three continents and has state-of-the-art processing facilities in Belgium, Germany, the Netherlands, Dubai, India and France (under construction). This information is provided by RNS The company news service from the London Stock Exchange END MSCXVLFLBEFZBBX
1 Year Cryo-Save Chart |
1 Month Cryo-Save Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions